# An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes

Study · id `cardio:ct-nct03216564` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03216564](<https://clinicaltrials.gov/study/NCT03216564>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03216564

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 320 participants.

## Technical summary

Registry record NCT03216564. Randomized; single masking; primary purpose treatment. Start 2017-05-10 (actual); primary completion 2019-05-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 320 participants (planned count; ClinicalTrials.gov record NCT03216564, source copy `cardio:ctgov-nct03216564-2018-09-06`, retrieved 2026-10-26)
- Started: 2017-05-10 (actual) (ClinicalTrials.gov record NCT03216564, source copy `cardio:ctgov-nct03216564-2018-09-06`, retrieved 2026-10-26)
- Primary completion: 2019-05-10 (anticipated) (ClinicalTrials.gov record NCT03216564, source copy `cardio:ctgov-nct03216564-2018-09-06`, retrieved 2026-10-26)
- Completion: 2019-05-10 (anticipated) (ClinicalTrials.gov record NCT03216564, source copy `cardio:ctgov-nct03216564-2018-09-06`, retrieved 2026-10-26)
- Countries: Qatar (ClinicalTrials.gov record NCT03216564, source copy `cardio:ctgov-nct03216564-2018-09-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03216564-2018-09-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes
- Acronym: IDEAL-2
- Condition: Diabetic Nephropathies
- Intervention (Drug): Calcitriol
- Lead sponsor: Hamad Medical Corporation
- Lead sponsor class: INDUSTRY
- Collaborator: Weill Cornell Medical College in Qatar
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Hamad Medical Corporation (`cardio:org-hamad-medical-corporation`)
- Registry lists this organization as a collaborator: Weill Cornell Medical College in Qatar (`cardio:org-weill-cornell-medical-college-in-qatar`)

## Provenance

Content hash: 51dada19d5929b0440fc6eaadd0fb49053f0fc748a9b06e522d3c04c18d8d5be
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
